Exercise of Share Options

15 October 2012

LiDCO Group Plc (AIM:LID), the UK-based hemodynamic monitoring company, announces that following the exercise of share options under the Company's EMI and unapproved schemes, LiDCO has issued a total of 447,000 new ordinary shares of 0.5 pence each.

Application has been made for 447,000 new Ordinary Shares to be admitted to trading on AIM, which will rank pari passu with the Company's existing Ordinary shares, and admission is expected to be effective on 19 October 2012 ("Admission").

Following admission of the new Ordinary Shares, the Company will have 176,108, 304 Ordinary Shares in issue with each share carrying the right to one vote. There are no shares held in Treasury. The total number of voting rights in LiDCO is therefore 176,108,304. This number may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or a change in their interest in, LiDCO under the Disclosure and Transparency Rules.

For further information, please contact:


LiDCO Group Plc
Terry O'Brien (CEO) Tel: +44 (0)20 7749 1500
Paul Clifford (Finance Director)
John Rowland (Company Secretary) www.lidco.com
FinnCap
Geoff Nash / Henrik Persson
Stephen Norcross (broking) 		Tel: +44 (0)20 7600 1658
www.finncap.com

Media enquiries:


Abchurch
Adam Michael / Joanne Shears / Simone Elviss / Jamie Hooper Tel: +44 (0) 20 7398 7728
simone.elviss@abchurch-group.com www.abchurch-group.com

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimization protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimization of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

•

early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

•

quantification of hemodynamic response,

•

guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

Clinical Validation & Education

LiDCO has been selected as the sole technology for two ongoing multi-centre government-funded studies in the UK and US. OPTIMISE is sponsored by the UK Government for optimizing cardiovascular management in high-risk abdominal surgery patients and in the US, MOnIToR is a US Government sponsored transplantation donor organ optimization study. The Company has also developed a hemodynamic workshop at St George's Hospital, London.

LiDCO Distribution Network:

LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.

LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.



distributed by